Consulting Services
Expert guidance for evidence generation, trial design, and regulatory strategies
Company profile
Company profile
TriNetX operates as the Global Truth Engine for Better Human Health, providing trusted real-world data and evidence solutions to life sciences, healthcare providers, and academic research institutions worldwide. Founded in 2013, the company has built the world's largest federated network of directly-sourced clinical data, connecting over 13,000 clinical sites across more than 20 countries and encompassing over 300 million patient lives with 94 billion clinical data points. Unlike traditional data aggregators, TriNetX maintains data within secure healthcare systems, preserving provenance, security, and granularity while enabling real-time querying and analysis. The company's flagship platform, TriNetX LIVE, provides researchers with immediate access to harmonized, research-ready healthcare data for cohort identification, feasibility studies, and real-world evidence generation. TriNetX combines advanced analytics and AI with rigorous scientific methodology, supported by world-renowned scientists who ensure findings withstand peer review and regulatory scrutiny. The platform serves pharmaceutical companies designing clinical trials and generating regulatory-grade real-world evidence, healthcare providers seeking to optimize care delivery and research capabilities, and academic institutions accelerating publication and grant funding success. TriNetX data has been cited in over 3,300 peer-reviewed publications, making it the world's most-cited data source in scientific journals. The company also offers EVIDEX for pharmacovigilance signal detection, specialized datasets with date-stamped granular data from 150M+ patients, and consulting services from industry experts. TriNetX's mission centers on providing transparent, traceable data and defensible evidence that stands up to the world's most rigorous scientific scrutiny, enabling faster drug development, improved patient outcomes, and accelerated medical research.
Company description TriNetX official website
Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
No clinical focus areas are currently listed.
Cloud Saas · Other deployment with recorded integration context.
Company milestones
TriNetX LIVE Network surpassed 300 million patients in June 2026, reflecting accelerating international growth
Partnerships
02 · Flagship portfolio
Selected source-backed Company products and the available commercial context.
Expert guidance for evidence generation, trial design, and regulatory strategies
Fine-grained, date-stamped data from 150M+ patients for deeper insights
Purpose-built platform for faster, more accurate signal detection and safety management
Web-based platform to define, explore, and analyze real-world data from 300M+ global patients
03 · Research intelligence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Journal of medical economics · Dec 1, 2026
Sex-related mortality differences in septic shock: A propensity score-matched study.Journal of critical care · Aug 1, 2026
Real-world analyses of bispecific antibodies and CAR-T cell therapy in relapsed or refractory multiple myeloma: a global TriNetX discovery and contemporary validation cohort.Leukemia & lymphoma · Jul 28, 2026
Pre-existing anxiety and mood disorders and multisystem outcomes in young adults with chronic kidney disease.Clinical kidney journal · Jul 1, 2026
Incidence of human papillomavirus infections in women aged 27 years and older in the US: A federated data network study.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · Jul 1, 2026
Directly comparing randomized and real-world controls in adjuvant breast cancer.Journal of comparative effectiveness research · Jun 1, 2026
Clinical validation
No linked records are currently available.
Regulatory
No linked records are currently available.
04 · Company-reported outcomes
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Citations using TriNetX data
TriNetX identified as data source
Global network coverage
Patients available for longitudinal analysis
Ensuring methodological rigor and credible study design when working with complex real-world EHR data
Accelerated data discovery and feasibility assessments; improved study robustness and reproducibility through rapid feasibility checks
Real-time querying in support of protocol optimization for clinical trials
Enabled real-time querying for protocol optimization goals
05 · Leadership
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Recent articles published on TriNetX's official website.
No Company updates are currently listed.
07 · HAIC coverage
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Curated official destinations from the active Company record.
09 · Market pathway
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Companies using AI to optimize clinical trial design, accelerate patient recruitment, match patients to trials, predict trial outcomes, or improve clinical research efficiency. Includes patient enrollment and screening platforms, AI-powered trial matching, and tools that reduce the time and cost of bringing new treatments to market.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.